Stock Market Reviews

VIR (Vir Biotechnology, Inc.) News

Get the latest news, insights, and market updates on VIR (Vir Biotechnology, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates
  Vir Biotechnology (VIR) delivered earnings and revenue surprises of -67.14% and -96.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 5, 2025 - $VIR
• Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
  SAN FRANCISCO, November 05, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2025.
  Nov 5, 2025 - $VIR
• Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
  SAN FRANCISCO, November 03, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in patients with chronic hepatitis delta (CHD). ECLIPSE 1 is one of three trials in Vir Biotechnology’s ECLIPSE registrational program for CHD, and it is designed to provide the efficacy and safety data needed for potential submission to global regulatory agencies, incl
  Nov 3, 2025 - $VIR
• With 59% ownership, Vir Biotechnology, Inc. (NASDAQ:VIR) boasts of strong institutional backing
  Key Insights Significantly high institutional ownership implies Vir Biotechnology's stock price is sensitive to their...
  Oct 28, 2025 - $VIR
• Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
  SAN FRANCISCO, October 22, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2025, on November 5, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on November 5, 2025.
  Oct 22, 2025 - $VIR
• Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains?
  Vir Biotechnology (VIR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
  Oct 9, 2025 - $VIR
• Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
  SAN FRANCISCO, October 09, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in Part 3 of the Company’s Phase 1 clinical trial evaluating VIR-5500 in combination with androgen receptor pathway inhibitors (ARPIs). VIR-5500 is an investigational PRO-XTEN® dual-masked T-cell engager (TCE) targeting prostate-specific membrane antigen (PSMA) and will be evaluated in participants in first-line pre-taxane metastatic castration-resistant prostate cancer (m
  Oct 9, 2025 - $VIR
• Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025
  SAN FRANCISCO, October 07, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present Week 48 endpoint results from the SOLSTICE Phase 2 clinical study evaluating tobevibart alone, or in combination with elebsiran, in patients with chronic hepatitis delta in an oral presentation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 in Washington, D.C., November 7-11. These results follow positive data presented at AASLD The
  Oct 7, 2025 - $VIR
• Vir Stock Soars After BofA Boosts Rating on Liver Therapy
  Analyst sees $1 billion+ peak sales, 215% upside potential
  Aug 27, 2025 - $VIR
• Micron initiated, Eli Lilly upgraded: Wall Street's top analyst calls
  Micron initiated, Eli Lilly upgraded: Wall Street's top analyst calls
  Aug 27, 2025 - $VIR